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RISK OF NAUSEA AND VOMITING IN PATIENTS WITH LYMPHOMA
UNDERGOING HIGH DOSE THERAPY WITH AUTOLOGOUS STEM CELL
RESCUE
Puto, M.1, Adel, N.1, Riedel, E.2, Giralt, S.A.3,4, Matasar, M.J.3,4 1Me-
morial Sloan-Kettering Cancer Center, New York, NY; 2Memorial
Sloan-Kettering Cancer Center, New York, NY; 3Memorial Sloan-Ket-
tering Cancer Center, New York, NY; 4Weil Cornell Medical College,
New York, NY
Background: Despite the use of 5-HT3 antagonists and corticoste-
roids, control of nausea and vomiting (N/V) from high-dose therapy
with autologous stem cell rescue (HDT) remains a clinical challenge.
Routine antiemetic prophylaxis atMemorial Sloan-KetteringCenter
(MSKCC) for pts undergoingHDT is continuous infusion ondanse-
tron and daily dexamethasone. Pts with lymphoma receiving HDT
receive conditioning based upon either RT or chemotherapy;
patients with regional disease may also receive hyperfractionated in-
volved-field RT immediately prior to HDT. The objective of this
study is to evaluate the incidence and predictors of nausea and vom-
iting in pts with lymphoma receiving HDT.
Methods:We performed a retrospective chart review of all sequen-
tial pts with lymphoma receiving HDT between 1/1/2004 and 12/
31/2009 via chart abstraction, review of the pharmacy database and
electronic medical record. Data collected include pt demographics,
diagnosis and therapy, social history, preparative regimen, prophy-
lactic and breakthrough antiemetic use, and instances of N/V. Vom-
iting was defined as recorded instances of vomiting, and nausea as
recorded instances of nausea.
Results: 280 pts were eligible for analysis (Table 1). 54 (19%)
received a TBI/TLI-based therapy, predominantly TLI with cy-
clophosphamide and etoposide, and 226 (81%) received chemo-
therapy-based therapy, predominantly BEAM (173/226, 77%);
immediately prior to conditioning, 83 (30%) received an involved
field RT boost to a site in the neck, chest, or abdomen. The in-
cidence of N/V during the hospital stay for HDT was 85%, and
during conditioning was 74%. 57% of patients had one or more
episodes of vomiting. Women were more likely to experience N/V
than men (94% vs. 80%, P\ 0.001). Patients receiving TBI/TLI-
based therapy had a greater incidence of N/V than did patients
receiving chemotherapy preparative regimens (P\ 0.01) and a lon-
ger duration of N/V (median days, 8 vs. 4). Pretransplant RT boost
was associated with a trend towards a greater incidence of N/V
(92% vs. 83%, P 5 0.09).
Conclusion: In our single-institution experience, pts with lym-
phoma undergoing HDT frequently experience N/V during their
hospitalization despite prophylaxis with ondansetron via continuous
infusion and dexamethasone. Pts receiving RT-based conditioning
or pre-transplant RT appear to be at greater risk yet of N/V. Addi-
tional research into anti-emetic prophylaxis in this patient popula-
tion should be a high priority.
Table 1. Clinical characteristics of patients with lymphoma
having received high-dose therapy with autologous stem cell
rescue
Chemotherapy- TBI- /(
Total
N 5 280)
based
(N-226)
T
(
LI-based
N 5 54)Age, median (range) 52 (18-73) 54 (18-73) 33 (20-64)
Gender
Male 171 (61%) 146 (65%) 25 (46%)
Female 109 (39%) 80 (35%) 29 (54%)
Diagnosis
Classical Hodgkin lymphoma 80 (29%) 33 (15%) 47 (87%)
Diffuse large B-cell lymphoma 74 (26%) 72 (32%) 2 (4%)
Mantle cell lymphoma 59 (21%) 56 (25%) 3 (6%)
Follicular lymphoma 21 (8%) 21 (9%) 0
Peripheral T-cell lymphoma 13 (5%) 12 (5%) 1 (2%)
Angioimmunoblastic T-cell lymphoma 9 (3%) 9 (4%) 0
Anaplastic large-cell lymphoma 6 (2%) 6 (3%) 0
Primary CNS lymphoma 9 (3%) 9 (4%) 0
Other 9 (3%) 8 (4%) 1 (2%)315
BUILDING A LEGACY
Bain,M.E., Kurtzberg, J., Cash, J., Martin, P.M. Duke UniversityMed-
ical Center, Durham, NC
Working with children who have life threatening conditions too
often leads to tragic endings. Being a Child Life Specialist (CCLS)
on a pediatric bone marrow transplant unit involves legacy building
and bereavement support for family and loved ones.
Historically, bereavement support at Duke Children’s Hospital
included, among many different things, hand/foot impressions using
plaster. These impressions are best done on infants and toddlers
(small hands). We were in need of a tool that we could use for
school-age and adolescent patients.
Our program helped develop a different kind of hand/foot mold
technique that is made with dental materials. In 2010, a grant was
awarded to the child life specialist working in the pediatric bone
marrow transplant unit to purchase these materials. This new tech-
nique allows for larger hand molds to be made (or multiple hands
at once). Often times, an entire family may want to hold hands and
have a mold made. The material called ‘‘alginate’’ is mixed with wa-
ter to create a paste inside a large disposable cup or basin. The
hand (or hands) is placed in the paste for approximately one minute
or until it hardens and then the hand(s) is removed. Resin rock is
then mixed and poured into the alginate impression. Within one
hour, the resin rock is dry and the alginate can be peeled away.
The child life specialist will then polish and wrap the molds for
presentation to the family.
We have been able to use this technique for .30 children since
2010. The feedback given to our team has been overwhelming. Fam-
ilies have expressed how they can now hold their child’s hand forever.
Some have been eager to emboss themolds in gold. Others have sim-
ply been happy to have something to hold onto as they walk away
from the hospital without their child.
Caring for the suffering and/or dying child is no easy journey. But
with a team of caregivers working together to build a child’s legacy, it
can be done beautifully, honoring the child’s precious life.316
ANXIETY IN BONE MARROW TRANSPLANT PATIENTS
Campos, M., Olaya, A. Instituo Nacional de Pediatria, Mexico, DF,
Mexico
Purpose:Clinical observation has proven that anxiety disorders fre-
quently appears in Bone Marrow transplant (BMT) patientes. It was
decided to conduct a study within the psychological transplant prep-
aration program (PTPP), where the pre-transplant anxiety level was
measured.
Method: A standardized psychological test battery and a semi-
structured interview were conducted on a group of 20 pediatric
patients (5 females/ 15 males, between 6 -18 years old) during
the first session prior to receiving any kind of PTPP. A record
was kept: Age, gender, diagnostic date, hospital stay, clinical com-
plications and family dynamic. Hypothesis testing was conducted
so as to compare percentages, establishing a specificity level f ~N
of 0.5 and a power of 0.8; therefore, estimation according to the
sample size, 20 patients, plus (less) 20% of losses during enroll-
ment was done. Regarding central distribution measurements, hy-
pothesis testing was conducted so as to compared means with
paired ¡V T.
Based on the results, a therapeutic support plan is developed for
handling the patient¡fs anxiety.
Results:Out of the 20 patients assessed, 80% of the patients have
a high anxiety level compared to their chronological age, accord-
ing to what the anxiety scale evaluates. 70% of patients had the
highest number of anxiety indicators within the tests. The statis-
tical analysis showed that variables: a) clinical complications, b)
hospital stay and c) family dynamics were the ones that had
a 90% influence in patients anxiety. Secondly, age, gender and di-
agnostic date were factors that influenced the anxiety status in
64% of the cases.
Conclusion: It is concluded that the anxiety level in BMT patients is
high from the moment they start the process, therefore, it is
Poster Session I S323important to give them coping techniques and in this way prevent
psychological complications in the next stages.317
A TASTE OF HOME FOR THE HOLIDAYS: PROVIDING A TRADITIONAL
HOLIDAY DINNER FOR INPATIENT STEM CELL TRANSPLANT PATIENTS
AND CAREGIVERS
Doyle, K. MD Anderson Cancer Center, Houston, TX
Background: Patients and caregivers undergoing hematopoietic
stem cell transplants (SCT) commit to long hospital stays, often last-
ing up to four weeks. During this time, patients, familymembers, and
caregivers are temporarily located in places other than their home
towns. This presents emotional, financial, and family challenges.
Holidays away from home are especially difficult, and may contrib-
ute to anxiety and depression.
Intervention: To support patients and caregivers who are away
from home and family, a large, comprehensive cancer center holds
a dinner between the major holidays of Thanksgiving and Christ-
mas. This has been a yearly event for the past 15 years. The din-
ner is planned, funded, and produced by the staff and aims to
provide a sense of home. The staff hosts fundraisers throughout
the year to support the dinner. The menu consists of both catered
and home-cooked dishes, mimicking the traditional American
holiday dinner. Staff members volunteer to set up, serve, and
clean up.
Evaluation: The holiday dinner has been beneficial for all who are
involved. Staff participation boosts morale and team spirit. Patients
and their caregivers are able to celebrate the holidays with their tem-
porary staff and fellow patient and caregiver family. The expressions
of heartfelt thanks and gratitude for the thoughtful efforts of the
staff, are almost overwhelming. Specific patient, caregiver, and staff
feedback will be shared.
Discussion: The annual holiday dinner serves as a means to pro-
vide patients and caregivers a dedicated time for social interaction
and a sense of normalcy during the stem cell transplant process.
Benefits of the holiday dinner for both patients and staff have as-
sured that the tradition has been passed on for 15 years, and will
continue.318
CYTOMEGALOVIRUS INFECTION OCCURRING BEFORE ENGRAFTMENT IN
RECIPIENTS OF ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANS-
PLANTATION FROM ALTERNATIVE DONORS
Cozzi, J., Basso, A., Saslavsky, J., Saslavsky, M., Prone, L. CETRAMOR
BMT-Unit, Rosario, Santa Fe, Argentina
Background: Cytomegalovirus (CMV) remains an important infec-
tious cause of morbidity and mortality among allogeneic Haema-
topoietic Stem Cell Transplantation (aHSCT) recipients (r).
CMV-seropositive r of transplants from alternative (A) donors are
at higher risk for very early onset of CMV infection (I) and disease
(D). Quantitative (q) polymerase chain reaction (PCR) assay for
CMVDNA in whole (W) blood (B) samples (S) is useful in identifing
patients (p) at risk for CMV-D before engraftment (E).
Methods: From 10/2008 to 10/2011 21 p who underwent A donor
aHSCT were studied. p in this cohort were tested bi-weekly by
qPCR assay for CMV DNA in WBS with a threshold for preemp-
tive (P) therapy (Th) at 500 copies (c)/ml (limit of detection). P Th
pre-E was started on IV foscarnet (F) 60 mg/Kg twice daily 14 days
as induction Th, followed by maintenance Th with 90 mg/Kg once
daily dosing until routine surveillance testing was negative. Age,
median (range) 28 (3-54) years. Male sex: 12 p (57%). Underlying
diseases: AML (6 p), ALL (6 p), CML (2 p), SAA (2 p), Inherited
Disorders of Metabolism (2 p), CMML (1 p), NHL (1 p), HL (1
p). D state at time of transplant: Refractory D: 12 p (57%),
CR.2nd: 5 p (24%). Conditioning Regimen: Reduced Intensity:
13 p (62%), Myeloablative: 8 p (38%). TBI (5 p)/TLI (8 p): 13p (62%). ATG (8 p)/CAMPATH-1H (3 p): 11 p (52%). Donors
Matched Unrelated (U): 5 p, Mismatched (MM) U: 6 p, MM
Related: 5 p, MM Umbilical Cord Blood (UCB): 5 p. Graft source:
peripheral blood stem cells: 16 p (76%), UCB: 5 p (24%). Graft-
versus-host disease (GVHD) prophylaxis: Cyclosporine + Myco-
phenolate Mofetil: 12 p (57%). Hyperacute GVHD 2 p (9,5%)
requiring high-doses corticosteroids. Acyclovir was given to Herpes
Simplex Virus seropositive r from the start of conditioning. CMV
serostatus: D+/R+: 12 p (57%), D-/R+: 9 p (43%). E was defined as
3 consecutive days with an absolute neutrophil (N) count .500
cells/uL.
Results: The median (range) time to N E was 19 (9-41) days. 8 p
(38%) developed CMV reactivation (R) prior to E. The median
(range) time to CMV-R was 12 (3-26) days. The median (range)
initial viral load in those p who developed CMV-R was 3.000
(500-10.000) c/ml. IV F was instituted as P antiviral Th in all p
who developed CMV-I pre-E. 1 p (4,8%) developed CMV-D (en-
cephalitis). None of these p died of CMV-D. F Th was not discon-
tinued in any p because of adverse effects.
Conclusion: Our study shows that a P treatment strategy based on
qPCR tests surveillance is safe and effective for treating CMV-I
ocurring before E in recipients of aHSCT from A donors.319
TRANSFUSION OF RED CELLS IN HEMATOPOIETIC STEM CELL TRANS-
PLANTATION: THE TRIST STUDY
Tay, J.1,2, Tinmouth, A.2, Fergusson, D.2, Allan, D.1 1Ottawa Hospital,
Ottawa, ON, Canada; 2University of Ottawa and Clinical Epidemiology
Program, Ottawa, ON, Canada
Background: Insight regarding transfusion practices inHematopoi-
etic Stem cell Transplantation (HSCT) are lacking, and the impact
of red blood cell (RBC) transfusion on outcomes following HSCT
are not well appreciated. A randomized study of transfusion is
required to gain insight on best transfusion practices in this
population.
Methods: In preparation for our trial, all adult transplant centres
associated with the Canadian Blood and Marrow Transplant Group
(CBMTG)(n 5 15) were asked to respond to a survey regarding
transfusion thresholds. Fourteen centres routinely transfuse 2 units
of RBCs when the hemoglobin\80 g/L and/or in response to pa-
tient specific indications while one centre transfuses RBCs when
the hemoglobin \70 g/L. The rationale for the near universal
adoption of red cell transfusion trigger of 80 g/L remains unclear.
Our centre has historically adopted a red cell transfusion trigger of
80 g/L and we conducted an audit of our practices for the year
2009. Despite our established trigger of 80 g/L, RBC transfusions
above this trigger occurred in 50% of all transplant patients ever
requiring red cells within the 1st 100 days of the transplant.
Further, 20% of all RBC transfusions occurred above the stated
trigger.
Results: Two of 5 invited CBMTG centres declined participation
for logistical reasons. In 3 centres, 100 patients undergoing HSCT
will be randomized to either a restrictive (target hemoglobin of 70-
90g/L) or liberal (target hemoglobin of 90-110g/L) RBC transfu-
sion strategy, based on daily hemoglobin values up to 100 days
post-transplant. The primary goal is to demonstrate study feasibil-
ity while collecting clinical outcomes on 1) Transfusion Require-
ments, 2) Transplant Related Mortality, 3) Maximum grade of
acute Graft versus Host Disease, 4) Veno-occlusive Disease, 5) Se-
rious Infections, 6) Bearman Toxicity Score, 7) Bleeding, 8) Qual-
ity of Life, 9) Number of Hospitalizations and Intensive Care Unit
admissions. At the time of writing, 25 patients have been followed
for 28 days post HSCT, with our 1st Data Safety Monitoring
Board review pending.
Conclusion: No CBMTG centre has clearly embraced a liberal
transfusion strategy and only 1 centre has embarked on a more re-
strictive strategy. This indicates some relative uncertainty with re-
gards to the benefits and harms of RBC transfusion in the HSCT
population. Upon completion, this pilot trial will provide
